【产品介绍】：

生物活性：Carboplatin-d4 is the deuterium labeled Carboplatin. Carboplatin (NSC 241240) is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Carboplatin-d4 相关抗体:
Ctip2 Antibody
Rb Antibody
Phospho-Rb (Ser807) Antibody
RPA32 Antibody (YA679)
CDT1 Antibody
DNA-PKcs/PRKDC Antibody
Hes1 Antibody
JunB Antibody
LIN28A Antibody
Lin28B Antibody
MCM2 Antibody
Nanog Antibody
Nucleolin Antibody
PCNA Antibody
PDX1 Antibody
RbBP5 Antibody
S100A4 Antibody
SP1 Antibody
BRCA1 Antibody (YA819)
Argonaute 2 Antibody
BRCA1 Antibody
Elongation Factor 1A1 Antibody
KAP1 Antibody
MCM2 Antibody (YA705)
MLH1 Antibody (YA703)
RNA Polymerase II Subunit B1 Antibody
RPA70 Antibody (YA678)
SP7/Osterix Antibody
DNA PKcs Antibody (YA957)
DNA PKcs Antibody (YA959)
分子量：375.28
Formula：C6H8D4N2O4Pt
非标记 CAS：41575-94-4
性状：固体
颜色：White to off-white
中文名称：卡铂 d4
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：-20°C, stored under nitrogen, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
纯度 & 产品资料
纯度： ≥99.0%
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Natarajan G, et al. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol. 1999 Nov 15;58(10):1625-9.
 [Content Brief]
[3]. Banerji U, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol. 2008 Oct;62(5):769-78.
 [Content Brief]
[4]. Clark CC, et al. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther. 2012 Sep;11(9):1948-58.
 [Content Brief]
[5]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116.
 [Content Brief]